



# Clinical Practice Guideline for the Care of Women with Decreased Fetal Movements

Developed in partnership with:



Endorsed by:



10 August 2017

**Produced by:**

**Endorsed by:**

## Table of Contents

|                                    |   |
|------------------------------------|---|
| Glossary of terms.....             | 1 |
| 1. Purpose of this guideline ..... | 3 |

## Glossary of terms

|                               |  |
|-------------------------------|--|
| <b>Acidaemia</b>              |  |
| <b>Amniotic fluid</b>         |  |
| <b>Antenatal</b>              |  |
| <b>Antepartum</b>             |  |
| <b>Apgar score</b>            |  |
| <b>Body mass index (BMI)</b>  |  |
| <b>Cardiotocography (CTG)</b> |  |
| <b>Congenital anomaly</b>     |  |
| <b>Customised birthweight</b> |  |

Flow cytometry

Gestation

## 1. Purpose of this guideline

## 2. Summary of clinical practice recommendations and care pathway

### 2.1 Recommendations for fetal movement monitoring

| Recommendations | Evidence level |
|-----------------|----------------|
|-----------------|----------------|

| Recommendations          | Evidence level and references* | Recommendation grade* |
|--------------------------|--------------------------------|-----------------------|
| <b>Recommendation 6</b>  |                                |                       |
|                          |                                |                       |
| <b>Recommendation 7</b>  |                                |                       |
|                          |                                | C                     |
| <b>Recommendation 8</b>  |                                |                       |
|                          |                                | B                     |
| <b>Recommendation 9</b>  |                                |                       |
|                          |                                | C                     |
| <b>Recommendation 10</b> |                                |                       |
|                          |                                |                       |
| <b>Recommendation 11</b> |                                |                       |
|                          |                                |                       |
| <b>Recommendation 12</b> |                                |                       |
|                          |                                |                       |





2.4 Clinical practice points for women presenting with decreased fetal movements from 28 weeks' gestation

Fetal to maternal haemorrhage

### 3. Background

#### 3.1 Maternal perception of fetal movement and adverse events

### 3.2 Perinatal mortality in Australia and New Zealand

perinatal mortality rate

perinatal related mortality rate

### **3.4 Investigations of DFM prior to 28 weeks' gestation**





6. Which investigations should be undertaken for DFM?

6.1 Fetal heart rate monitoring

| Recommendations  | Evidence level and references | Recommendation grade |
|------------------|-------------------------------|----------------------|
| Recommendation 4 |                               |                      |





decreased fetal movements

no fetal movements

### 6.3 Fetal to maternal haemorrhage and DFM

Recommendation 11



## 8. Discussion: Implementation and future research

## 9. References











**Appendix A. Risk factors for stillbirth in high-income country settings**

| Factor | aOR (95% CI) | PAR* (%) |
|--------|--------------|----------|
|        |              |          |

---

**Notes**

in a population

Lancet

BMJ

## Appendix B. Methods for guideline development



## Appendix D. Level of evidence & grading of recommendations

### Levels of Evidence

| Level       | Description |
|-------------|-------------|
| Level I     |             |
| Level II    |             |
| Level III-1 |             |
| Level III-2 |             |
| Level III-3 |             |

### Body of Evidence Matrix<sup>122</sup>

| Component                  | A         | B    | C            | D    |
|----------------------------|-----------|------|--------------|------|
|                            | Excellent | Good | Satisfactory | Poor |
| Evidence base <sup>1</sup> |           |      |              |      |
| Consistency <sup>2</sup>   |           |      |              |      |
| Clinical impact            |           |      |              |      |
| Generalisability           |           |      |              |      |
| Applicability              |           |      |              |      |

**Appendix E. Guideline working party**

| Name | Role and/or affiliation |
|------|-------------------------|
|      |                         |





## Appendix G. Stakeholder consultation